I’d like to introduce you to Jeff Ubben, the Valeant Pharmaceuticals of hedge fund managers. Wait...nevermind, you get the point. This is a short post, but packed with must-know, must-read info. First is a look at Jeff Ubben’s ValueAct 13D performance. This is part of the activist performance database we’re pumping. You can read more about it a recent blog post on our happenings. Performance- Ubben has killed it. His average 13D is up 23.5% annualized. All his closed 13D campaigns have returned 20% annually but one. C.R. Bard didn’t work out. His Valeant position is a big standout with a 58% CAGR, but there’s plenty of other winners, including Verisign, Rockwell Collins and Gardner Denver - all with 50% CAGRs. Open 13D campaign wise, 21st Century Fox and Allison Transmissions are the two most interesting ones to me. Goodreads on Ubben- Jeff Ubben on what he learned from Peter Lynch [link] h/t @valuewalk@PainCapital thoughts on Ubben [https://twitter.com/PainCapital/status/624603114121748481!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");]Ubben taking a swipe at Barry Rosenstein at 2014 Milken [] h/t @jay_21_@Emory_R notes and long-form Ubben interview [link] h/t @jeffubben@AlderLaneeggs on Jeff Ubben [https://twitter.com/jeffubben/status/624321426888110080!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");] h/t @jeffubbenJeff Ubben thesis on Valeant Pharma from 2010 [link] h/t @AnthonyMorley12@jay_21_ thoughts on Ubben: “Listened to a few Ubben interviews 2 good concepts: 1) ensure equity rep is on BoD 2) don’t buy at a control premium but exit at one.”Our thoughts on Jeff Ubben and his 21st Century Fox thesis [link] Don't forget - sign up for our free daily newsletter to stay in the activist investing know.